EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MetALD : New Perspectives on an Old Overlooked Disease

Gustavo Ayares iD, Luis Antonio Diaz iD, Francisco Idalsoaga iD, Naim Alkhouri iD, Mazen Noureddin iD, Ramon Bataller iD, Rohit Loomba iD, Juan Pablo Arab iD, Marco Arrese iD

Liver International · 2025-05 · 45 (5)

DOI: 10.1111/liv.70017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 03.04.2025. Verfasst von Gustavo Ayares und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: Alcohol Drinking, Liver Diseases, Alcoholic, Fatty Liver. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease (ALD) are the major contributors to the liver disease burden globally. The rise in these conditions is linked to obesity, type 2 diabetes, metabolic syndrome and increased alcohol consumption. MASLD and ALD share risk factors, pathophysiology and histological features but differ in their thresholds for alcohol use, and the ALD definition does not require the presence of metabolic dysfunction. A recent multi‐society consensus overhauled the nomenclature of liver steatosis and introduced the term MetALD to describe patients with metabolic dysfunction who drink more than those with MASLD and less than those with ALD. This new terminology aims to enhance the understanding and management of liver disease but poses challenges, such as the need to accurately measure alcohol consumption in research and clinical practice settings. Recent studies show that MetALD has significant implications for patient management, as it is associated with increased mortality risks and more severe liver outcomes compared to MASLD alone. MetALD patients face increased risks of liver disease progression, cancer and cardiovascular disease. The diagnosis of MetALD involves the adequate quantification of alcohol use through standardised questionnaires and/or biomarkers as well as proper assessment of liver disease stage and progression risk using non‐invasive tools including serologic markers, imaging, elastography techniques and genetic testing. Effective management requires addressing both metabolic and alcohol‐related factors to improve outcomes. This review intends to provide a comprehensive overview of MetALD, covering pathogenesis, potential diagnostic approaches, management strategies and emerging therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alcohol DrinkingLiver Diseases, AlcoholicFatty LiverHumansRisk FactorsTerminology as TopicDisease ProgressionMetabolic Syndrome

Stichwörter der Autor:innen

MASLDNAFLDalcoholic liver diseasealcohol‐related liver diseaseametabolic dysfunction‐associated steatotic liver diseasecirrhosisalcoholic cirrhosisnon‐alcoholic fatty liver disease

Autor:innen und Institutionen

  • Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Escuela de Medicina, Universidad Finis Terrae, Santiago, Chile.
  • MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, California, USA.
  • Division of Gastroenterology Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada.
  • Department of Hepatology, Arizona Liver Health, Chandler, Arizona, USA.
  • Houston Methodist Hospital, Houston, Texas, USA.

ORCID-Profile: Gustavo Ayares, Luis Antonio Diaz, Francisco Idalsoaga, Naim Alkhouri, Mazen Noureddin, Ramon Bataller, Rohit Loomba, Juan Pablo Arab, Marco Arrese

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Ayares, G., Diaz, L. A., Idalsoaga, F., Alkhouri, N., Noureddin, M., Bataller, R., Loomba, R., Arab, J. P., & Arrese, M. (2025). MetALD : New Perspectives on an Old Overlooked Disease. Liver International, 45(5). https://doi.org/10.1111/liv.70017

Vancouver

Ayares G, Diaz LA, Idalsoaga F, Alkhouri N, Noureddin M, Bataller R, et al. MetALD : New Perspectives on an Old Overlooked Disease. Liver International. 2025;45(5). doi:10.1111/liv.70017

BibTeX
@article{Ayares2025,
  author = {Ayares, Gustavo and Diaz, Luis Antonio and Idalsoaga, Francisco and Alkhouri, Naim and Noureddin, Mazen and Bataller, Ramon and Loomba, Rohit and Arab, Juan Pablo and Arrese, Marco},
  title = {MetALD : New Perspectives on an Old Overlooked Disease},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {5},
  doi = {10.1111/liv.70017}
}
Kostenlos starten →